Hep C Treatment

Hepatitis C: Treatment and Management


Decentralized HCV Treatment is Effective!

Given the safety, tolerability, simplicity, and efficacy of hepatitis C direct-acting antiviral (DAA) regimens, decentralizing treatment from gastroenterologists and hepatologists to other specialists, community-based primary care physicians, or appropriately supervised mid-level providers (ie, task-shifting) may be an effective strategy to increase treatment rates, cure rates, and really start addressing to the HCV epidemic. The SVR-12 rates ...

Read More


C-SALVAGE: Final 24-week Follow-up Results

Non-cross-resistant drugs are needed for salvage therapy of patients with chronic hepatitis C virus infection who do not achieve sustained virologic response on direct acting antiviral (DAA) regimens. The final follow-up week 24 results from the C-SALVAGE study (Hepatitis C-Salvage Study for Patients who Failed DAA/PR Therapy), have been published in the journal Clinical Infectious Diseases (Buti M, et al. Clin Infect Dis. 2015 Sep 14. [Epub ...

Read More


Tx Options for HCV GT 1 or 4 Non-responders

New study shows that genotype 1- or 4-infected non-responders, including patients with cirrhosis, achieve high SVR12 rates on the 24 week, quad treatment regimen of daclatasvir plus asunaprevir and peginterferon/ribavirin. The combination was well tolerated and no additional safety and tolerability concerns were observed compared with peginterferon/ribavirin regimens. A combination of Direct Acting Antivirals (DAAs) and peginterferon/ribavirin ...

Read More


Two DAA regimen in cirrhotic HCV GT1b patients

New Phase 2 clinical trial results indicate that an all-oral interferon- and ribavirin-free regimen of ombitasvir, paritaprevir, and ritonavir is generally well tolerated and associated with high rates of SVR12 in both cirrhotic and noncirrhotic patients with HCV genotype 1b infection who were treatment-naive or treatment experienced, including prior null responders, a population for whom antiviral treatment information has been lacking. HCV ...

Read More


GS-5816: a DAA with pan-genotypic HCV activity

The availability of a safe, highly effective, pangenotypic regimen for the treatment of HCV infection would have a major impact on global disease prevalence, as it would be suitable for treatment of all infected persons regardless of genotype. Results of a new phase 1 study demonstrate the safety and potent pan-genotypic HCV activity of GS-5816, a novel inhibitor of the HCV nonstructural NS5A protein. GS-5816 administered at doses ranging from 5 ...

Read More


Real-world impact of sofosbuvir HCV regimens

New study addresses the real-world effectiveness of sofosbuvir (SOF)-based anti-HCV regimens in a diverse patient population consisting of difficult to treat patients. More than a quarter of the assessed US Veterans Affairs (VA) population with chronic HCV infection were African American, almost 90% were over the age of 55, over a third were overweight, and substantial proportions were treatment experienced and had advanced liver disease. ...

Read More


HCV DAAs and Severe Renal Impairment

New report provides vital information needed by clinicians to treat HCV in patients with severe renal impairment with the approved DAAs simeprevir and sofosbuvir. Available clinical information on the use of sofosbuvir in patients with severe renal impairment is minimal, and there are currently no approved direct acting antiviral (DAA) treatments in this population. A report recently published online in Journal of Hepatology details the ...

Read More


Hepatitis C RAVs are Not a Barrier to Retreatment

Study published in the journal Hepatology suggests that sofosbuvir plus peginterferon and ribavirin for 12 weeks is effective and safe in patients who have not achieved SVR with prior regimens of one or more direct-acting antiviral (DAA) agents plus peginterferon and ribavirin. High rates of SVR12 are achieved regardless of the presence of resistance associated variants (RAVs) to the previous agents (Pol S, et al. Hepatology. 2015 Apr 6. doi: ...

Read More


Beneficial Effect of Statins on HCV Infection

In a large, national cohort study assessing the impact of statin use upon progression of fibrosis in an unselected group of patients with various stages and genotypes of HCV, controlling for known confounders, statin use was significantly associated with decreased progression of fibrosis independent of having attained an SVR. This is the first study to demonstrate that statin use is significantly associated with increased SVR rates and decreased ...

Read More


Barriers to Accessing HCV Therapies in the US

Recent study indicates that newly available, interferon-free HCV therapies will significantly increase access to care for HCV infected individuals in the US, as unlike standard interferon-based therapies, interferon-free therapies are associated with minimal contraindications. However, a large proportion of US individuals with chronic hepatitis C infection are uninsured or under-insured, and this lack of adequate insurance coverage ...

Read More